TABLE 1.
Background of participants
| All | AGEs‐low | AGEs‐high | P value | |
|---|---|---|---|---|
| n | 447 | 224 | 223 | |
| Age, median (IQR) | 58 (49–65) | 57 (49–64) | 59 (51–67) | 0.040 |
| Male, n (%) | 170 (38%) | 65 (29%) | 105 (47%) | <0.001 |
| BMI (kg/m2) | 23 (21–25) | 23 (20–26) | 23 (21–25) | 0.220 |
| Somatic fat rate, % | 26 (20–31) | 27 (13–31) | 25 (20–31) | 0.193 |
| Hypertension (HTN) | 252 (56%) | 127 (57%) | 125 (56%) | 0.891 |
| Cardiovascular disease (CVD) | 30 (6.7%) | 10 (4.5%) | 20 (8.9%) | 0.087 |
| Diabetes mellitus (DM) | 41 (56%) | 13 (5.8%) | 28 (13%) | 0.021 |
| Sleeping tablet user, n | 18 (4.0%) | 6 (2.7%) | 12 (5.4%) | 0.228 |
| IPSS | 2 (1–6) | 2 (1–5) | 2 (1–6) | 0.950 |
| Nocturia > 1, n | 70 (16%) | 33 (15%) | 37 (17%) | 0.603 |
| PSQI score > 5, n | 62 (14%) | 34 (15%) | 28 (13%) | 0.412 |
| AGEs, median (IQR) | 1.80 (1.34–2.21) | 1.34 (1.32–1.55) | 2.21 (1.97–2.53) |
Abbreviations: AGEs, advanced glycation end products; IQR, interquartile range, IPSS, International Prostate Symptom Score; PSQI, Pittsburgh Sleep Quality Index.